Creating a new mental health treatment paradigm

Leaders in psychedelic
drug development

Since 2017, Ceruvia Lifesciences, founded by Carey Turnbull, has focused on the discovery, development, and commercialization of transformational medicines to deliver meaningful relief to patients suffering from psychiatric and neurological disorders. Leveraging the expertise of some of the world’s leading medical schools, combined with a team of highly experienced drug development professionals, our clinical drug development program is creating new transformational medical breakthroughs.

Carey Turnbull

Founder & CEO

OUR FOUNDER

Carey Turnbull has over a decade of experience in early-stage drug development on behalf of half a dozen companies variously as an investor, founder, and CEO. Early philanthropic donors supporting psychedelic science and research, Carey and Claudia Turnbull have been deeply involved in the development of better treatment options for those suffering from psychiatric and neurological disorders.

In addition to his roles as Founder and CEO of B. More and Ceruvia Lifesciences, Carey is the chair of the advisory board to NYU’s Center for Psychedelic Medicine and a board member of the Heffter Research Institute.

Paul Bezodis

COO

OUR COO

Paul is a seasoned freelance clinical research professional bringing over 25 years of global experience across all phases of human trials. He has contributed to top-tier pharmaceutical companies, pioneering biotech firms, and both large-scale and boutique contract research organizations.

For the past four years, Paul has been leading the team and the European program at MAPS Europe B.V. Chief among his achievements at MAPS Europe was the completion of the first ever European phase 2 trial for MDMA-assisted therapy (MDMA‑AT) for post-traumatic stress disorder (PTSD).

BOARD OF DIRECTORS

Stephen Hurst

Kathleen (Kay) Monroe

David Steinberg

Contact

CONTACT CERUVIA

Stay informed of Ceruvia news and research

Please enter Your Email

Contact